Pfizer-BioNTech ask EU agency to OK vaccine for kids 5-11


In this June 6, 2021 file photo, a youth receives a Pfizer-BioNTech COVID-19 vaccine in the central Israeli city of Rishon LeZion. The pharmaceuticals Pfizer and BioNTech say they have requested that their coronavirus vaccine be licensed for children aged 5 to 11 across the European Union. If authorized, it would be the first opportunity for younger children in Europe to be get immunized against COVID-19. (AP Photo/Sebastian Scheiner)

BERLIN (AP) — Pharmaceutical company Pfizer and biotechnology company BioNTech said Friday they have requested to have their coronavirus vaccine licensed for children ages 5 to 11 across the European Union. If EU regulators agree, it would be the first opportunity for younger children in Europe to get immunized against COVID-19.

Pfizer and BioNTech said they submitted data to the European Medicines Agency, including late-stage results from a study testing their COVID-19 vaccine in more than 2,200 children ages 6 months to 11 years. The children received a lower dose than what’s normally given to adults.

The companies said in a statement that the results showed a “strong immune response” in the children and that the vaccine was also found to be safe. There are currently no COVID-19 vaccines licensed for use in children younger than 12 in Europe or North America; the ones made by Pfizer-BioNTech and Moderna are authorized for children 12 and older in the European Union.

Earlier this month, Pfizer and BioNTech asked the U.S. Food and Drug Administration to greenlight their vaccine for children ages 5 to 11.

Expanding vaccine availability to roughly 28 million more U.S. children was seen as another milestone in the fight against the virus and comes amid an alarming rise in serious infections in youngsters because of the extra-contagious delta variant.

In the United States, COVID-19 has killed at least 520 children so far, according to the American Academy of Pediatrics.

With much of Europe's adult population already immunized, many countries are seeing increasing outbreaks of the disease in children while schools are mostly open and operating with sometimes patchy guidance on mask-wearing and social distancing.

The World Health Organization has said that vaccinating children was not a priority because they are far less likely to develop serious disease or to die of COVID-19. The health agency has repeatedly urged rich countries to share their doses with poor countries instead of expanding domestic eligibility so the world's vulnerable populations can be immunized.

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
4.9782 of 5 stars
$25.26-3.8%6.65%70.17Hold$36.33
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

7 Stocks to Help You Build Off January’s Gains

7 Stocks to Help You Build Off January’s Gains

It's frequently said that as January goes, so goes the market. If that's the case, it's time for investors to put money to work in the stock market.

Search Headlines: